Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated December 22, 2025. The report serves as a vehicle to disseminate a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Marseille, France, and files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text contains only the cover page and exhibit index. It does not include the content of the press release or any financial statements. Consequently, no data is available regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. The nature of the update is limited to the issuance of a press release, the content of which is not included in the source text.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, and contingencies are not present in the provided text. The document solely confirms the authorization of the report by Jonathan Dickinson, Chief Executive Officer.
Investor Verification Checklist
- Verify the full content of the press release dated December 22, 2025 (Exhibit 99.1), as the summary text does not contain the announcement details.
- Confirm whether the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements, which are typical for this biopharmaceutical issuer.
- Check subsequent filings for any financial impact resulting from the announcement made on this date.